Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Real-time Reminders To Decrease Late or Missed Meal Boluses (Klue)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03970889
Recruitment Status : Active, not recruiting
First Posted : June 3, 2019
Last Update Posted : February 28, 2020
Sponsor:
Information provided by (Responsible Party):
Bruce Buckingham, Stanford University

Brief Summary:
This study is examining whether the Klue app is effective in detecting missed or late meal boluses in patients with Type 1 diabetes. The app is programmed onto an Apple Watch and will detect potential missed boluses from hand motion. It will send text alerts to the user asking if they have bolused. This is a pilot study and will assess whether there is a change in the number of missed meal boluses in the two weeks prior to each visit. If the findings are significant, this software can be integrated in future closed-loop algorithms for automatic insulin delivery.

Condition or disease Intervention/treatment Phase
Type1 Diabetes Mellitus Device: Klue Not Applicable

Detailed Description:
This will be a randomized, cross-over, unblinded study with subjects randomized upon entry into the study to either begin using the Klue software for 6 weeks or to continue with their usual care for 6 weeks. Subjects are eligible for enrollment if they are using a continuous glucose monitor (CGM) and insulin pumps or an insulin pen with memory and CGM, are missing or late in giving at least 4 food boluses in the previous two weeks, and they have an iPhone. Missing or late meal boluses will be assessed through their pump/pen and sensor downloads. This is a pilot study. The investigators do not have preliminary data to do a true power calculation. The primary outcome will be the change in the number of missed meal boluses in the two weeks prior to each visit. Secondary outcome measures will be the number of missed meal boluses in each month of the study, change in HbA1c levels (measured every 6 weeks), accuracy of the Klue software in detecting meals (true positive and false positive rates), and a user satisfaction survey.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 24 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Intervention Model Description: Subjects are randomized so that half will use the Klue App in the first 6 weeks of the study, and half will use the Klue App during the second 6 weeks of the study.
Masking: None (Open Label)
Primary Purpose: Supportive Care
Official Title: Pilot Study to Test Efficacy of Real-time Reminders on Apple Watch To Decrease Late or Missed Meal Boluses
Actual Study Start Date : October 12, 2018
Estimated Primary Completion Date : March 30, 2020
Estimated Study Completion Date : March 30, 2020

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
No Intervention: Standard Care
Participants will be in their usual care, wearing a continuous glucose sensor and taking insulin by pump or by pens with memory
Experimental: Klue
Subjects will wear an Apple watch on their dominant hand and receive alerts when eating behavior is detected by the Klue software.
Device: Klue
Klue is a software program the uses an Apple watch to detect hand motions which are indicative of eating.




Primary Outcome Measures :
  1. Change in the number of missed meal boluses [ Time Frame: The two weeks prior to each study visit ]
    A missed meal bolus is defined by no insulin dose within 2 hours from the start of the CGM rise.


Secondary Outcome Measures :
  1. Change in time in range [ Time Frame: data for 1 month prior to each study visit at baseline, 6 weeks and 12 weeks of this 12 week study for each subject ]
    sensor glucose values between 70-180 mg/dl

  2. Positive predictive value of a Klue meal alert [ Time Frame: All data for the 6 weeks on the Klue intervention arm when Klue is active ]
    Percent of time a meal alert signaled a meal



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   13 Years and older   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Age 13 and over
  2. On an insulin pump for at least 3 months and using CGM or using an insulin pen with memory and a CGM
  3. Willing to wear a CGM at least 70% of the time while in the study
  4. Using an iPhone
  5. Willing to wear an Apple watch on their dominant hand while awake
  6. Missing or late in giving at least four food boluses in the previous two weeks
  7. Understanding and willingness to follow the protocol and sign informed consent
  8. Ability to speak, read and write in the language of the investigators

Exclusion Criteria:

  1. Pregnant or lactating
  2. A known medical condition that in the judgment of the investigator might interfere with the completion of the protocol
  3. Current treatment for a seizure disorder
  4. Inpatient psychiatric treatment in the past 6 months

Note: Adequately treated thyroid disease and celiac disease do not exclude subjects from enrollment. They may be participating in another trial, if this study is approved by the investigators of the other trial.


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03970889


Locations
Layout table for location information
United States, California
Stanford
Palo Alto, California, United States, 94305
Sponsors and Collaborators
Stanford University
Investigators
Layout table for investigator information
Principal Investigator: Bruce Buckingham, MD Stanford University
Publications:
Layout table for additonal information
Responsible Party: Bruce Buckingham, Professor of Pediatric Endocrinology, Stanford University
ClinicalTrials.gov Identifier: NCT03970889    
Other Study ID Numbers: 47137
First Posted: June 3, 2019    Key Record Dates
Last Update Posted: February 28, 2020
Last Verified: February 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Diabetes Mellitus, Type 1
Diabetes Mellitus
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Autoimmune Diseases
Immune System Diseases